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Background: Arterial Tortuosity Syndrome (ATS) is a very rare autosomal recessive connective tissue disorder (CTD)
characterized by tortuosity and elongation of the large- and medium-sized arteries and a propensity for aneurysm
formation and vascular dissection. During infancy, children frequently present the involvement of the pulmonary
arteries (elongation, tortuosity, stenosis) with dyspnea and cyanosis. Other CTD signs of ATS are dysmorphisms,
abdominal hernias, joint hypermobility, skeletal abnormalities, and keratoconus. ATS is typically described as a severe
disease with high rate of mortality due to major cardiovascular malformations. ATS is caused by mutations in the
SLC2A10 gene, which encodes the facilitative glucose transporter 10 (GLUT10). Approximately 100 ATS patients have
been described, and 21 causal mutations have been identified in the SLC2A10 gene.
Case presentation: We describe the clinical findings and molecular characterization of three new ATS families,
which provide insight into the clinical phenotype of the disorder; furthermore, we expand the allelic repertoire of
SLC2A10 by identifying two novel mutations. We also review the ATS patients characterized by our group and
compare their clinical findings with previous data.
Conclusions: Our data confirm that the cardiovascular prognosis in ATS is less severe than previously reported and
that the first years of life are the most critical for possible life-threatening events. Molecular diagnosis is mandatory
to distinguish ATS from other CTDs and to define targeted clinical follow-up and timely cardiovascular surgical or
interventional treatment, when needed.
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Arterial Tortuosity Syndrome (ATS; MIM #208050) is a
very rare autosomal recessive connective tissue disorder
(CTD) characterized mainly by tortuosity and elongation
of the large and medium-sized arteries and a propensity
for aneurysm formation and vascular dissection. Disease
onset usually occurs in infancy or early childhood [1-6].
Additional cardiovascular features include the aberrant
origin of aortic branches, pulmonary valve and pulmon-
ary arteries stenosis, and vasomotor instability. ATS also
has additional signs that are shared with other CTDs,
i.e., Marfan syndrome (MFS), Loeys-Dietz syndrome
(LDS), Cutis laxa (CL) and Ehlers-Danlos syndromes
(EDS), including soft/velvety/hyperextensible skin, cutis
laxa, mildly dysmorphic facial features (i.e., elongated
face, hypertelorism, cleft palate and/or bifid uvula, and
micro/retrognathia), abdominal hernias, joint hypermo-
bility, congenital contractures and other skeletal anoma-
lies [2-9]. Several patients died at a young age owing
mainly to cardiopulmonary complications such as acute
respiratory insufficiency and right ventricular (RV) hyper-
tension and hypertrophy, resulting in congestive heart
failure, myocarditis and ischemic events leading to organ
infarction [3]. Stenosis of the pulmonary arteries (PAS) oc-
curs in 60% of the patients [5], and in severe cases, there
is significant obstruction to RV output, causing RV hyper-
tension and dysfunction. All ATS patients require regular
follow-up and may benefit from surgical interventions, i.e.,
aortic root replacement for aortic aneurysms; pulmonary
artery reconstruction has yielded good clinical and hemo-
dynamic outcomes in specific patients [5,10-15].
ATS is caused by mutations in the SLC2A10 gene en-
coding the 541-amino-acid facilitative glucose trans-
porter 10 (GLUT10) [4]. GLUT10 belongs to the SLC2A
transporter family and facilitates the uptake of D-glucose,
D-galactose and 2-deoxy-D-glucose, and dehydroascorbic
acid (DHA) [16-18]. Here, we report the clinical findings
and molecular characterization of three novel ATS fam-
ilies with acute respiratory symptoms in infancy and de-
scribe two novel SLC2A10 mutations. We compare the
clinical features of the patients with previous data to eluci-




Patients were evaluated by pediatric cardiologists, clin-
ical geneticists and dermatologists. Written informed
consent was obtained for each proband and family mem-
ber before sample collection for genetic analyses. Spe-
cific consent was obtained for publication of the clinical
data including photographic documentation. This study
was approved by the medical ethics committee of the
University Hospital Spedali Civili of Brescia and wasperformed in accordance with the Declaration of Helsinki
Principles.
Although the three evaluated ATS families lacked con-
sanguinity, the parents of three patients had a common
geographical origin. In the first family, the proband was a
14-year-old Italian boy, his older brother was unaffected.
In the second family, the probands were two Macedonian
8- and 6-year-old brothers born after an elder healthy
brother. In the third Italian family, the patient clinically di-
agnosed with ATS died at 26 months of age during cardio-
vascular surgery; his healthy parents were characterized by
SLC2A10 genetic testing. The main clinical features of the
four patients are shown in Table 1.
Methods
Mutation screening
Genomic DNA was extracted from peripheral blood
leukocytes using standard procedures; the exons and
intron-flanking regions of the SLC2A10 gene were PCR
amplified and directly sequenced using an ABI3130XL
Genetic Analyzer. Segregation was verified in all families;
the causal mutations were absent in a panel of 200 healthy
donors. The nucleotide and protein accession numbers
correspond to the SLC2A10 (NM_030777.3; NP_110404.1)
reference sequence. Mutations were annotated according
to the HGVS nomenclature (www.hgvs.org/mutnomen).
Nucleotide numbering is based on the cDNA sequence
numbering, with +1 corresponding to the A of the ATG
translation initiation codon 1 in the reference sequence.
For protein numbering, +1 corresponds to the first
translated amino acid. We used the mutation-prediction
programs MutationTaster (www.mutationtaster.org),
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2), pro-
ject HOPE (http://sift.jcvi.org/), SIFT (www.sift.jcvi.org)
and Alamut version 2.2 to evaluate causality based on al-
teration of the protein structure.
Results
Clinical findings
Patient 1 (Family A). The 14-year-old Italian proband
was born following an uneventful pregnancy and deli-
very. The weight at birth was 4.2 kg, which was in the
50th-75th centile. He presented with cyanosis spontaneously
resolved (Table 1). His perinatal period and psychomotor
development were normal. The patient’s hypertrophic py-
loric stenosis was surgically corrected at 40 days of age.
Severe RV hypertension due to stenotic and tortuous pul-
monary artery branches was resolved by surgical arterio-
plasty at 1 year of age (Figure 1, i) and with stenting of
pulmonary arteries at 8 years. Aortography performed dur-
ing the interventional cardiac catheterization revealed an
elongated and tortuous aorta and tortuous brachiocephalic
vessels (Figure 1, j) as well as mild mitral valve regurgita-
tion. Keratoconus and myopia were diagnosed at 5 years.
Table 1 Summary of the main clinical features of the ATS patients described in this study
Patient 1 Patient 2 Patient 3 Patient 4




hypertension due to PAS
1 month/cyanosis 3 months/respiratory failure and cyanosis
due to PAS
First months/cyanosis after feeding
Dysmorphisms
Elongated face + + +
Scaphocephaly (mild) + - -
Beaked nose + + +
Micro-retrognathia + + +
High-arched palate - + +
Uvula abnormalities + + (bifid) + (elongated)
Skin
Doughy + + +
Hyperextensible + - -
Atrophic scars + + -
Cardiovascular
Tortuosity PA, Brachiocephalic vessels Intraparenchymal PA, aortic arch, ascending
aorta, brachiocephalic vessels
Intraparenchymal PA, aortic thoracic tract PA, supra-aortic vessels, aortic arch
Pulmonary arteries
defects
Stenotic peripheral PA Marked tortuosity of intraparenchymal PA,
stenosis of pulmonary branches
Tortuosity of intraparenchymal PA, dilatation
of main PA and central branches
Tortuosity of PA, dilatation of pulmonary
trunk
RV hypertension + Birth - + 50 mmHg + 110 mmHg
RV anomalies + + Dilatation + Hypertrophy, left ventricle compression + Dilatation
Valvular regurgitation Mitralic, mild Tricuspidal, mild Tricuspidal, mild Tricuspidal, mild
Surgery Reconstructive surgery of pulmonary
vessels at 1 years; stenting of PA at
2 years
- - Reductive pulmonary arterioplasty with
stenting of PA branches




+ - - -
Keratoconus + - -
Joint hypermobility
(Beighton score)


















Figure 1 Clinical and angiographic features of Patient 1: mild scaphocephaly, elongated face, beaked nose, microretrognathia, elongated
philtrum with congenital angioma, large ears (a,b), winged scapulae, scoliosis (c,d), hyperextensible skin over the neck (e), atrophic scar over the
right the knee and elbow (f,g), and brachydactyly type D (h). An angiographic study performed between the pulmonary vessel reconstructive
surgery and the following stenting revealed the tortuosity of the aorta and the origin of the brachiocephalic vessels (i) and the narrow origin of
the pulmonary artery branches and their tortuous course (j).
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at 14 years of age: elongated face, beaked nose, large
ears, microretrognathia, elongated philtrum, congenital
angioma over the philtrum, high-arched palate, doughy
skin, atrophic scars over the right knee and the elbows,
striae distensae over the glutei, brachydactyly type D, pa-
tella hyperlaxity, absence of joint hypermobility accord-
ing to the Beighton score (0/9), leg-length discrepancy,
winged scapulae, scoliosis, and genua valga (Figure 1, a-h).
Patient 2 (Family B). The 8-year-old Macedonian boy
was born following an uneventful pregnancy and delivery.
His psychomotor development was normal. At 1 month
of age, he presented with severe respiratory distress and
cyanosis (Table 1). Easy bruising, dyspnea after physical
exercise, and chronic fatigue syndrome were observedthroughout his childhood. A heart ultrasound performed
at 8 years of age revealed mild RV dilatation and mild
tricuspidal regurgitation. A heart magnetic resonance an-
giography (MRA) revealed an irregular ascending aorta,
marked tortuosity of the intraparenchymal pulmonary ar-
teries, and PAS (Figure 2A, d,e). The systolic pulmonary
artery pressure was normal.
On examination at 8 years, the patient’s height was
1.23 m (10th-25th centile), and his weight was 22 kg
(10th-25th centile). The dysmorphic features were large
and protruding ears, elongated face, microretrognathia,
(Figure 2A, a,b), epicanthal folds, blepharophimosis,
high-arched palate, and elongated uvula with median
raphe. The skin was doughy and poorly hyperextensible;
small atrophic scars were present over the left knee,
Figure 2 Clinical and radiological features of Patients 2 and 3. A) Patient 2: mild scaphocephaly, hypotelorism, large ears, elongated face,
micro-retrognathia, winged scapulae, scoliosis (a,b), genua valga, easy bruising, small atrophic scar over left knee (c), tortuosity of aortic arch and
brachiocephalic vessels (d), marked tortuosity of intraparenchymal arteries (e). B) Patient 3: mild scaphocephaly, epicanthus, hypotelorism, large
ears, elongated face, microretrognathia (a,b), winged scapulae, scoliosis (c), pes planus, piezogenic papules (d), right ventricular hypertrophy with
left ventricular compression (e), marked tortuosity of intraparenchymal arteries (f).
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(Figure 2A, c). The skeletal signs included joint hyper-
mobility according to the Beighton score (7/9), mild pec-
tus excavatum, scoliosis, winged scapulae (Figure 2A, b),
patella hyperlaxity, genua valga, and pedes plani.
Patient 3 (Family B). The 6-year-old Macedonian pa-
tient was born following an uneventful pregnancy and
delivery. His psychomotor development was normal. At
3 months of age, he presented with respiratory failure
and cyanosis secondary to peripheral PAS; severe dys-
pnea and cyanosis recurred in his childhood after mod-
erate physical exercise, and easy bruising and chronic
fatigue syndrome also occurred (Table 1). A heart ultra-
sound revealed mild tricuspidal regurgitation, RV hyper-
trophy and left ventricular compression. At 6 years of age,
a heart MRA revealed dilatation of the main pulmonary
artery and central branches, tortuosity and stenosis of the
intraparenchymal pulmonary arteries and high systolic
pressure in the central pulmonary arteries (50 mmHg, n.v.
15–30) (Figure 2B, e). Furthermore, the aortic thoracic
tract had a tortuous appearance (Figure 2B, f).
On examination at 6 years of age, his height was
1.15 m (25th-50th centile) and weight was 20 kg (25th -50th
centile). The observed dysmorphisms included large
ears, elongated face, microretrognathia, high palate
(Figure 2B, a,b), and elongated uvula; the skin was
doughy and poorly hyperextensible; small atrophic scars
were present over the knees, and ecchymoses were ob-
served in the pretibial region; piezogenic papules were
present on the heels (Figure 2B, d). The skeletal signs
included joint hypermobility according to the Beighton
score (5/9), mild pectus excavatum, winged scapulae,
scoliosis (Figure 2B, c), patella hyperlaxity, genua valga,
and pedes plani.
Patient 4 (Family C). The patient was brought in for
medical attention in the first months of life because of
cyanosis after feeding, and in-depth vascular studies
were performed (Table 1). At 4 months of age, aortogra-
phy and pulmonography revealed tortuosity of the supra-
aortic vessels, aortic arch, and pulmonary arteries, which
also showed severe stenosis. A heart ultrasound performed
at 20 months of age revealed left ventricular hypertrophy
and severe pulmonary hypertension (110 mmHg) with RV
and pulmonary trunk dilatation. A clinical diagnosis of
ATS was made. At 26 months of age, the child was admit-
ted for cardiovascular surgery, and reductive pulmonary
arterioplasty with stenting of the pulmonary artery bran-
ches was performed. An intraoperative examination re-
vealed marked dilatation of the pulmonary trunk, which
was three times larger than the ascending aorta. When the
patient was weaned from extracorporeal circulation, the
patient died as a result of secondary decompensation lead-
ing to impaired cardiac contractile function and subse-
quent cardiac arrest.Molecular analyses
In Patient 1 (Family A), sequencing analysis revealed
the homozygous c.1309G>A transition in exon 3 of the
SLC2A10 gene; both parents of the proband were hetero-
zygous for this mutation (Figure 3). This causal mutation
was previously identified in compound heterozygosis in
another Italian patient and substitutes a glutamic acid
residue with a basic lysine residue (p.Glu437Lys) at the
second position of the 5th intracellular GLUT10 loop; the
glutamic acid residue at this position is highly conserved
in all members of the SLC2A glucose transporter gene
family and in SLC2A10 orthologs in other species [8].
In Patients 2 and 3 (Family B), SLC2A10 genotyping
revealed the homozygous novel c.254T>C transition in
exon 2, resulting in the p.Leu85Pro missense mutation;
both parents of these probands were heterozygous for
this mutation (Figure 3). In silico prediction algorithms
(SIFT score 0.01, MutationTaster p value 1.000, Poly-
Phen2 HumDiv score 0.999, HumVar score 0.977, and
Grantham score 98) characterized the p.Leu85Pro sub-
stitution as deleterious and probably damaging. This
mutated and highly conserved residue is located in the
3th transmembrane domain (TMD3) and is located near
the recurrent p.Ser81Arg missense mutation [4,19].
During prenatal genetic counseling in Family C, gen-
etic testing revealed that the parents of Patient 4 were
heterozygous carriers of the novel mutation c.1465G>C
(Figure 3). This transversion occurs in exon 4 of the
SLC2A10 gene, substituting a neutral glycine residue
with a positively charged arginine residue (p.Gly489Arg)
in the last transmembrane domain (TMD12) of the
GLUT10 protein. The in silico prediction algorithms
(SIFT score 0.01, MutationTaster p value 0.999, Poly-
Phen2 HumDiv score 0.976, HumVar score 0.898, and
Grantham score 125) characterized the p.Gly489Arg
substitution as deleterious and probably/possibly dam-
aging. This molecular characterization allowed the pre-
natal analysis of a chorionic villus sample in the second
pregnancy, which revealed that the fetus was heterozy-
gous for the familial mutation.
Discussion
ATS, first described by Ertrugul in 1967 [20] and Beuren
et al., in 1969 [21], is a very rare CTD caused by reces-
sive SLC2A10 mutations. Approximately 100 ATS pa-
tients have been reported, including those from inbred
multiplex families in Italy, Morocco, Saudi Arabia, and
Qatar [4,7,19,22,23]. The majority of the reported ATS
patients are infants or children [2,5,9,23,24]. A total of
23 mutations have been identified in the SLC2A10 gene:
12 missense substitutions, 5 nonsense nucleotide changes,
5 deletions leading to frame-shifts and premature ter-
mination codon formation and one splice mutation
([4-9,19,23,25-27], this study) (Figure 4 and Additional file 1:
Figure 3 Molecular characterization. Sequencing of SLC2A10 exons and splice junctions revealed the following: Patient 1 was homozygous for
the recurrent mutation c.1309G>A (p.Glu437Lys) in exon 3; Patients 2 and 3 were homozygous for the novel mutation c.254T>C (p.Leu85Pro) in
exon 2; the parents of Patient 4 were heterozygous for the novel mutation c.1465G>C (p.Gly489Arg) in exon 4.
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lying all the SLC2A10 mutations is the loss of GLUT10
function, the specific role of the GLUT10 transporter in
ATS pathogenesis is still controversial. Similar to other
conditions known as TGF-β vasculopathies (MFS, which
is caused by FBN1 mutations and LDS, which is caused by
TGFBR1, TGFBR2, SMAD3 and TGFB2 mutations), the
SLC2A10 loss of function activates the TGF-β signaling
pathway [4,28]. Considering that GLUT10 is a putative
DHA transporter, diminished GLUT10 activity in ATS
might lead to structural abnormalities in the arterial wall
proteins such as collagens and elastin due to a reduction
in hydroxylated prolines and lysines or to oxidative stress
injury caused by elevated production of reactive oxidative
species. These abnormalities would result in pathogenic
vascular remodeling [17,18]. However, in both the “endo-
plasmic reticulum – enzyme cofactor” and “mitochondrial
– antioxidant” models of vitamin C-related pathology, theexact interaction with the TGF-β pathway in ATS remains
unclear and requires further study [29,30].
The clinical findings of the ATS patients described in
this study and the families previously characterized by
our group are summarized in Additional file 2: Table S2
[2,4,6,8-12,31]. These patients constitute a unique cohort
of clinically and molecularly defined Italian ATS pa-
tients, with the exception of the two Macedonian broth-
ers described here. Our cohort comprised 12 patients
from 8 different families; consanguineous relationships
were present in two of these families. Apart from arterial
tortuosity, that is present in all patients of our cohort,
the signature features of ATS seem to be a facies suis
generis including a long face, malar hypoplasia, a beaked
nose, and micrognathia, as well as a high frequency of
PAS observed in 75% of the patients (9/12). In addition
to these hallmarks, ATS has several somatic features
shared with other CTDs; therefore, clinical diagnosis can
Figure 4 Graphical overview of all known SLC2A10 mutations. GLUT10 contains 12 hydrophobic TMDs (rectangles), a hydrophilic endofacial
loop between TMDs 6 and 7 as well as a large hydrophilic loop containing a putative N-linked glycosylation site between TMDs 9 and 10. The
two novel mutations identified in this study are indicated in bold letters. The numbering is based on the protein reference sequence
NP_110404.1.
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angiography, and MRA and/or CT scan. The somatic
signs of CTDs in our cohort comprised easy bruising
(9/9), doughy skin (9/11) with generally mild hyperex-
tensibility (4/10), joint hypermobility (9/11), relapsing
hernias (7/12), valvular regurgitation (8/10), and kera-
toconus (3/8). Aortic aneurysms might not be a signa-
ture feature of ATS because aneurysms were observed
only in 3 patients, and dissections did not occur. A
small aneurysm of the splenic artery was observed in
the patient of Family D at 51 years of age, and an ascend-
ing and aortic root aneurysm was observed in 2 members
of Family H, respectively. The mild splenic artery aneu-
rysm and the ascending aneurysms did not require sur-
gery, whereas a valve-sparing aortic root replacement was
performed to prevent further aortic dilation and rupture
in the patient of family H at 19 years of age [11].
In our cohort, the mean age at clinical examination
was approximately 15 years. Eleven patients, 7 males
and 4 females, are still alive with a mean age of approxi-
mately 23 years. One patient died at 26 months of age
following cardiovascular surgery for PAS. Four of the
surviving patients are children with a mean age of ap-
proximately 9 years, and seven are adults with a mean
age of approximately 31 years, including a 55-year-old
patient. Therefore, consistent with the study by Callewaert
et al., [5], in our cohort, the most striking observation is
that the life expectancy of patients with ATS is longer
than initially observed [3]. Wessels et al., [3] observed that
ATS is fatal before the age of 5 years in 40% of patients.
This conclusion was based on a review of 35 ATS patients;
26 of these patients were observed previously and had a
high rate of consanguinity [1,10,20,21,32-37]; the other 9patients were novel cases from 3 other consanguineous
families. Subsequently, Callewaert et al., [5] described 16
new patients with defined SLC2A10 mutations and with a
low rate of consanguinity (25%); the mean age of these pa-
tients (13 years) was greater than previous observations,
and only one patient died at 33 years of age, most likely
from an unrelated cause. One potential reason for the ini-
tial bias towards low life-expectancy/high mortality rate
might be the lack of molecular confirmation in the pa-
tients studied by Wessel et al., [3]; these patients were
studied before the casual gene was identified [4]. Molecu-
lar testing is often mandatory to distinguish ATS from
other CTDs with strictly overlapping clinical signs and
with high rates of life-threatening cardiovascular events
such as LDS or autosomal recessive CL [38,39]. Further-
more, the high rate of consanguinity in the families
studied by Wessel et al., [3] might have worsened the
phenotype. Finally, in recent years, increased knowledge
on the disease has facilitated targeted follow-ups and
timely cardiovascular surgery when needed, leading to im-
proved prognosis. Therefore, the first few years of life
might be critical for potentially life-threatening events
[26,27,40]. Callewaert et al., [5] observed that 4 out of 16
patients had cyanosis in the first few months of life, and
one patient experienced a stroke at 8 months of age. Fur-
thermore, in our cohort, the first clinical presentation, i.e.,
acute respiratory symptoms such as cyanosis or respira-
tory distress occurred in the majority of the cases (50%) at
birth or during the first few months of life. All the new
patients described in this study presented with severe
cardiopulmonary complications in infancy, and in one
case, these complications were fatal. Because PAS is the
most dangerous cardiovascular feature in ATS patients,
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ectly related with the degree of PAS. Al-Khaldi et al., [14]
described 7 pediatric patients with bilateral peripheral and
central PAS with systemic to supra-systemic RV pressure
and severe RV dysfunction. All these patients underwent
successful surgical repair for reconstruction of the pul-
monary arterial tree, indicating that this is an excellent
and safe strategy for severe ATS patients. In our cohort,
combined surgical and interventional treatment allowed
Patient 1 (Family A) and patient of Family F [12] to reach
adolescence in a good hemodynamic condition without
any pharmacologic support with only mildly elevated RV
pressure and good RV and LV function and to lead a nor-
mal life including all activities appropriate to their age
(NYHA class I). The same hybrid surgical procedure was
adopted also for Patient 4, unfortunately the patient died
during weaning from extracorporeal circulation as a result
of secondary decompensation leading to impaired cardiac
contractile function. However, to our knowledge [11,12]
and based on a literature review [13-15], complications
have not been observed during cardiovascular surgery in
ATS patients, and the risk of fatal events should be similar
to the general population. Together, these data suggest
that in ATS, an early diagnosis is life saving, leading to
proper management and follow-up. Specific complications
that may appear in adulthood include chronic systemic
and pulmonary hypertension, heart conduction defects,
aortic root dilatation, stroke, and intracranial aneurysms
[2,5,9,11,24]. These features that occur later during life ne-
cessitate specific attention and management. In addition
to the use of vascular imaging (MRA and/or CT scan) as
previously described [5], specific additional less-invasive
follow-up procedures might include periodic measure-
ment of systemic blood pressure, ECG, and heart ultra-
sound with aortic root diameter measurements [9].
The obstetric aspects of ATS have not been elucidated.
Allen et al., [41] reported a 27-year old ATS woman with
successful pregnancy. In our cohort, 3 out of 4 women
had pregnancies without complicated deliveries. These
data suggest that in ATS, pregnancy can be safely han-
dled with multidisciplinary management including close
maternal and fetal surveillance.
Conclusions
In conclusion, our data confirm that cardiovascular pro-
gnosis in ATS is less severe than previously reported and
that the first few years of life are the most critical for
possible life-threatening events, i.e., acute respiratory
symptoms, due mostly to complications of PAS. Molecu-
lar diagnosis is mandatory to distinguish ATS from other
CTDs with strictly overlapping clinical signs and with a
high rate of more severe cardiovascular events and to
define targeted clinical follow-up and timely cardiovascu-
lar surgery when needed. Further studies on the functionalproperties of GLUT10 are required to elucidate the patho-
genic mechanisms involved in ATS etiology to identify po-
tential therapeutic options.
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